Currently out of the existing stock ratings of Steve Chesney, 20 are a BUY (43.48%), 6 are a SELL (13.04%), 20 are a HOLD (43.48%).

Steve Chesney

Work Performance Price Targets & Ratings Chart

Analyst Steve Chesney, carries an average stock price target met ratio of 59.54% that have a potential upside of 25.23% achieved within 384 days. Previously, Steve Chesney worked at ATLANTIC EQUITIES.

Steve Chesney’s has documented 91 price targets and ratings displayed on 9 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on BMY, Bristol-Myers Squibb Company at 06-Feb-2024.

Wall Street Analyst Steve Chesney

Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 12/1/2022. The price target of $295 was fulfilled within 4 days with a profit of $6.85 (2.27%) receiving and performance score of 5.67.

Average potential price target upside

of $90.25 (23.28%) on IDXX (IDEXX LABORATORIES).
of $50.63 (17.26%) on BIIB (BIOGEN).
of $25.26 (30.64%) on ABBV (ABBVIE).

BIIB Biogen ABBV AbbVie AMGN Amgen BMY Bristol-Myers Squibb Company JNJ Johnson & Johnson MRK Merck mpany IDXX IDEXX Laboratories PFE Pfizer ZTS Zoetis

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Ami Fadia (NEEDHAM)